Pages that link to "Q54535188"
Jump to navigation
Jump to search
The following pages link to The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. (Q54535188):
Displaying 200 items.
- The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer (Q26744721) (← links)
- KRAS oncogene in lung cancer: focus on molecularly driven clinical trials (Q26765353) (← links)
- PI3K/Akt/mTOR inhibitors in breast cancer (Q26771394) (← links)
- Treatment Individualization in Colorectal Cancer (Q26776215) (← links)
- Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers (Q26781362) (← links)
- Molecular phenotypes of colorectal cancer and potential clinical applications (Q26785725) (← links)
- Splicing Regulators and Their Roles in Cancer Biology and Therapy (Q26798158) (← links)
- What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway (Q26825780) (← links)
- Pathways and therapeutic targets in melanoma (Q26865736) (← links)
- Targeted therapies in development for non-small cell lung cancer (Q27022852) (← links)
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma (Q27852994) (← links)
- Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade (Q27853295) (← links)
- Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression (Q27853310) (← links)
- Maximising the potential of AKT inhibitors as anti-cancer treatments (Q28072254) (← links)
- Combination treatment including targeted therapy for advanced hepatocellular carcinoma (Q28077738) (← links)
- Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? (Q28079596) (← links)
- RSK3: A regulator of pathological cardiac remodeling (Q28086916) (← links)
- Cytoprotection "gone astray": Nrf2 and its role in cancer (Q28393784) (← links)
- Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs (Q28547522) (← links)
- Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK (Q28833740) (← links)
- PI3K and cancer: lessons, challenges and opportunities (Q30080017) (← links)
- Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. (Q30252408) (← links)
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies (Q33408049) (← links)
- Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors (Q33439312) (← links)
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors (Q33571352) (← links)
- The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo (Q33591361) (← links)
- Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer (Q33591690) (← links)
- Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways (Q33687272) (← links)
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development (Q33776641) (← links)
- Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models (Q33820374) (← links)
- Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. (Q33825288) (← links)
- Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo (Q34075366) (← links)
- The MAPK pathway as an apoptosis enhancer in melanoma (Q34104135) (← links)
- Oncogenic KRAS signalling in pancreatic cancer (Q34113460) (← links)
- Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations (Q34153696) (← links)
- MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer (Q34203585) (← links)
- Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells (Q34223118) (← links)
- Development of siRNA payloads to target KRAS-mutant cancer (Q34287993) (← links)
- Novel somatic mutations to PI3K pathway genes in metastatic melanoma (Q34389570) (← links)
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors (Q34525925) (← links)
- miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. (Q34599550) (← links)
- mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers (Q34673900) (← links)
- A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors (Q34818301) (← links)
- Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models (Q35018805) (← links)
- Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas (Q35033377) (← links)
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors (Q35051964) (← links)
- Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. (Q35068021) (← links)
- mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma (Q35236736) (← links)
- Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. (Q35462692) (← links)
- Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer (Q35657842) (← links)
- A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study (Q35748507) (← links)
- Molecular markers predictive of chemotherapy response in colorectal cancer (Q35761956) (← links)
- Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. (Q35775241) (← links)
- CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. (Q35892362) (← links)
- Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer (Q35980053) (← links)
- A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer (Q35987286) (← links)
- Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles. (Q36092046) (← links)
- Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia (Q36093878) (← links)
- Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening (Q36192485) (← links)
- Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle. (Q36219160) (← links)
- TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression (Q36413746) (← links)
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma (Q36437111) (← links)
- PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials (Q36510935) (← links)
- RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. (Q36525647) (← links)
- Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. (Q36544152) (← links)
- The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence (Q36546319) (← links)
- mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer (Q36546669) (← links)
- Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity (Q36613302) (← links)
- An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine (Q36621726) (← links)
- Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma (Q36685569) (← links)
- Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway (Q36771848) (← links)
- miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling (Q36814884) (← links)
- The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer (Q36820568) (← links)
- RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer (Q36891050) (← links)
- PIK3CA mutations in advanced cancers: characteristics and outcomes (Q36926111) (← links)
- Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. (Q36985083) (← links)
- Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. (Q37017190) (← links)
- Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. (Q37060963) (← links)
- A combinatorial strategy for treating KRAS-mutant lung cancer (Q37080881) (← links)
- Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer (Q37165886) (← links)
- Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer (Q37203121) (← links)
- ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas (Q37225222) (← links)
- miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer. (Q37236236) (← links)
- Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. (Q37281508) (← links)
- Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer (Q37301776) (← links)
- It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma (Q37308813) (← links)
- MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. (Q37381179) (← links)
- Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. (Q37421296) (← links)
- Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer (Q37451255) (← links)
- PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer (Q37655023) (← links)
- Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer (Q37665359) (← links)
- Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. (Q37679937) (← links)
- MEK1 is required for the development of NRAS-driven leukemia (Q37696978) (← links)
- Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells (Q37702589) (← links)
- Safety and feasibility of targeted agent combinations in solid tumours (Q38077440) (← links)
- Development of PI3K inhibitors: lessons learned from early clinical trials (Q38080710) (← links)
- Phosphoinositide 3-kinase α inhibitors: a patent review (Q38089138) (← links)
- Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine (Q38096413) (← links)
- Molecular-targeted agents combination therapy for cancer: developments and potentials (Q38104670) (← links)
- Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer (Q38112122) (← links)
- Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma (Q38124821) (← links)
- Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma (Q38148747) (← links)
- Prospects for MEK inhibitors for treating cancer. (Q38193520) (← links)
- Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer (Q38242086) (← links)
- Glioblastoma: molecular pathways, stem cells and therapeutic targets (Q38393328) (← links)
- Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies (Q38641329) (← links)
- Biomarkers in Melanoma: Lessons from Translational Medicine (Q38652178) (← links)
- Drugging the 'undruggable' cancer targets (Q38667658) (← links)
- Phosphoproteomics in translational research: a sarcoma perspective. (Q38708614) (← links)
- Targeting mTOR for the treatment of B cell malignancies (Q38709825) (← links)
- Engineering nanolayered particles for modular drug delivery. (Q38711119) (← links)
- Combine and conquer: challenges for targeted therapy combinations in early phase trials. (Q38734451) (← links)
- Gastric cancer management: Kinases as a target therapy (Q38749038) (← links)
- Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy. (Q38835111) (← links)
- Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers (Q38847931) (← links)
- Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress. (Q38946538) (← links)
- Molecular signaling cascades involved in nonmelanoma skin carcinogenesis (Q38966698) (← links)
- The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro (Q38983353) (← links)
- Drug Combinations as the New Standard for Melanoma Treatment. (Q38987086) (← links)
- The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. (Q38995499) (← links)
- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways (Q38997002) (← links)
- Neomorphic mutations create therapeutic challenges in cancer. (Q39007820) (← links)
- Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway (Q39018168) (← links)
- Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. (Q39167351) (← links)
- Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma (Q39277209) (← links)
- Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor (Q39286336) (← links)
- mTOR Signaling Confers Resistance to Targeted Cancer Drugs. (Q39456830) (← links)
- Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC). (Q40809231) (← links)
- TrkC promotes colorectal cancer growth and metastasis (Q41093090) (← links)
- Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways (Q41146978) (← links)
- Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways (Q41667581) (← links)
- Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease (Q41777292) (← links)
- Dual targeting of MEK and PI3K pathways attenuates established and progressive pulmonary fibrosis. (Q41894002) (← links)
- YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis (Q42034441) (← links)
- MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. (Q42354586) (← links)
- MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma (Q42608339) (← links)
- Academically led clinical trials: challenges and opportunities (Q43245004) (← links)
- The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. (Q44073293) (← links)
- Selective targeting of point-mutated KRAS through artificial microRNAs (Q45058705) (← links)
- The PI3K Pathway in Human Disease (Q46546002) (← links)
- Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice (Q47105237) (← links)
- Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells (Q47122504) (← links)
- Correlation between MEK signature and Ras gene alteration in advanced gastric cancer (Q47145152) (← links)
- Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. (Q47772398) (← links)
- Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors (Q47782406) (← links)
- Impact of genomics on the surgical management of melanoma. (Q50010320) (← links)
- Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression (Q50326703) (← links)
- Pseudolaric acid B inhibits gastric cancer cell metastasis in vitro and in haematogenous dissemination model through PI3K/AKT, ERK1/2 and mitochondria-mediated apoptosis pathways. (Q50926241) (← links)
- Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. (Q50981985) (← links)
- Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. (Q51029604) (← links)
- miR-1193 Suppresses Proliferation and Invasion of Human Breast Cancer Cells Through Directly Targeting IGF2BP2. (Q51402350) (← links)
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. (Q51514665) (← links)
- Challenges and opportunities in childhood cancer drug development. (Q51549131) (← links)
- Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. (Q53098366) (← links)
- PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. (Q53705802) (← links)
- Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. (Q54108752) (← links)
- The PI3K/AKT/mTOR interactive pathway. (Q54274892) (← links)
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. (Q54308330) (← links)
- Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. (Q54314770) (← links)
- Sphingolipid content in the human uterus and pair-matched uterine leiomyomas remains constant. (Q54465674) (← links)
- Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells. (Q54977616) (← links)
- Targeting PP2A in cancer: Combination therapies (Q58542302) (← links)
- Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway (Q58587446) (← links)
- Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine (Q58610296) (← links)
- Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway (Q58712167) (← links)
- Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment (Q58786537) (← links)
- Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors (Q60301870) (← links)
- mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer (Q60395350) (← links)
- Therapeutic opportunities for pain medicines via targeting of specific translation signaling mechanisms (Q60680291) (← links)
- MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment (Q61796853) (← links)
- MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival (Q62746316) (← links)
- MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer (Q64053811) (← links)
- DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties (Q64057563) (← links)
- Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer (Q64108445) (← links)
- ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma (Q64241934) (← links)
- Regression of BRAF V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. (Q64898821) (← links)
- Hyaluronic Acid Layered Chimeric Nanoparticles: Targeting MAPK-PI3K Signaling Hub in Colon Cancer Cells. (Q64921561) (← links)
- Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways. (Q64964634) (← links)
- Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. (Q64980814) (← links)
- Advances in the pharmacological activities and mechanisms of diosgenin (Q85855984) (← links)
- New insights from the widening homogeneity perspective to target intratumor heterogeneity (Q88682253) (← links)
- Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells (Q89156992) (← links)
- The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K (Q89448868) (← links)
- Silencing of PTEN inhibits the oxidative stress damage and hippocampal cell apoptosis induced by Sevoflurane through activating MEK1/ERK signaling pathway in infant rats (Q89846977) (← links)
- Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research (Q89993964) (← links)
- An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer (Q90134792) (← links)
- Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors (Q90292840) (← links)
- Pathogenesis and Clinical Management of Uterine Serous Carcinoma (Q90399148) (← links)
- RAS, wanted dead or alive: Advances in targeting RAS mutant cancers (Q90629924) (← links)
- Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer (Q91735283) (← links)
- Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy (Q92076388) (← links)
- Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma (Q92211141) (← links)
- Short-Term Environmental Conditioning Enhances Tumorigenic Potential of Triple-Negative Breast Cancer Cells (Q92360152) (← links)
- Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling (Q92393013) (← links)
- Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches (Q92504704) (← links)
- Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations (Q92508283) (← links)
- Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma (Q92610920) (← links)
- Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer (Q92659554) (← links)
- Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial-Mesenchymal Transition in Cancer (Q92755864) (← links)
- Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy (Q97542726) (← links)